UNSPSC 51272301: Etoxadrol

This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SIQ2UWR01K, chemically known as piperidine, 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl)- (9ci) but generally known as etoxadrol, which bears US NIH Compound Identifier 19324. European Medicines Agency schedules Etoxadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07341MIG.

UNSPSC 51272301 Etoxadrol is a Commodity code tracking pharmaceutical products, though recent state and local solicitations tagged under this code reflect a broader pattern: jurisdictions are procuring naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing mechanisms. The buying bodies range from county health departments (Seminole County, Florida) to state health and human services agencies (Texas HHS Commission) to multistate cooperative alliances (Minnesota Multistate Cooperative Purchasing Alliance), with health agencies and public health initiatives driving demand. Procurement focuses on supply agreements with defined pricing models, wholesaler relationships, and compliance certifications including Good Manufacturing Practices and Drug Supply Chain Security Act adherence; vendors must maintain insurance, E-Verify authorization, and electronic ordering capability.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to support community health initiatives. Texas HHS issued an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription programs and vendor capabilities for self-insured employers and state agencies. Minnesota's MMCAP alliance posted an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement. Awards under the MMCAP solicitation were effective July 1, 2026, with a two-year term and optional extensions.